Venclexta FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved April 11, 2016)
Brand name: Venclexta
Generic name: venetoclax
Dosage form: Tablets
Company: AbbVie Inc.
Treatment for: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Venclexta (venetoclax) is an oral B-cell lymphoma-2 (BCL-2) inhibitor indicated:
- for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Development timeline for Venclexta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.